BACKGROUND: Understanding the factors associated with HIV drug resistance development and subsequent mortality is important to improve clinical patient management. METHODS: Analysis of individual electronic health records from 4 HIV programs in Malawi, Kenya, Uganda, and Cambodia, linked to data from 5 cross-sectional virological studies conducted among patients receiving first-line antiretroviral therapy (ART) for ≥6 months. Adjusted logistic and Cox-regression models were used to identify risk factors for drug resistance and subsequent mortality. RESULTS: A total of 2257 patients (62% women) were included. At ART initiation, median CD4 cell count was 100 cells per microliter (interquartile range, 40-165). A median of 25.1 months after therapy start, 18% of patients had ≥400 and 12.4% ≥1000 HIV RNA copies per milliliter. Of 180 patients with drug resistance data, 83.9% had major resistance(s) to nucleoside or nonnucleoside reverse transcriptase inhibitors, and 74.4% dual resistance. Resistance to nevirapine, lamivudine, and efavirenz was common, and 6% had etravirine cross-resistance. Risk factors for resistance were young age (<35 years), low CD4 cell count (<200 cells/μL), and poor treatment adherence. During 4978 person-years of follow-up after virological testing (median = 31.8 months), 57 deaths occurred [rate = 1.14/100 person-years; 95% confidence interval (CI): 0.88 to 1.48]. Mortality was higher in patients with resistance (hazard ratio = 2.08; 95% CI: 1.07 to 4.07 vs. <400 copies/mL), and older age (hazard ratio = 2.41; 95% CI: 1.24 to 4.71 for ≥43 vs. ≤34 years), and lower in those receiving ART for >30 months. CONCLUSIONS: Our findings underline the importance of optimal treatment adherence and adequate virological response monitoring and emphasize the need for resistance surveillance initiatives even in HIV programs achieving high virological suppression rates.
BACKGROUND: Understanding the factors associated with HIV drug resistance development and subsequent mortality is important to improve clinical patient management. METHODS: Analysis of individual electronic health records from 4 HIV programs in Malawi, Kenya, Uganda, and Cambodia, linked to data from 5 cross-sectional virological studies conducted among patients receiving first-line antiretroviral therapy (ART) for ≥6 months. Adjusted logistic and Cox-regression models were used to identify risk factors for drug resistance and subsequent mortality. RESULTS: A total of 2257 patients (62% women) were included. At ART initiation, median CD4 cell count was 100 cells per microliter (interquartile range, 40-165). A median of 25.1 months after therapy start, 18% of patients had ≥400 and 12.4% ≥1000 HIV RNA copies per milliliter. Of 180 patients with drug resistance data, 83.9% had major resistance(s) to nucleoside or nonnucleoside reverse transcriptase inhibitors, and 74.4% dual resistance. Resistance to nevirapine, lamivudine, and efavirenz was common, and 6% had etravirine cross-resistance. Risk factors for resistance were young age (<35 years), low CD4 cell count (<200 cells/μL), and poor treatment adherence. During 4978 person-years of follow-up after virological testing (median = 31.8 months), 57 deaths occurred [rate = 1.14/100 person-years; 95% confidence interval (CI): 0.88 to 1.48]. Mortality was higher in patients with resistance (hazard ratio = 2.08; 95% CI: 1.07 to 4.07 vs. <400 copies/mL), and older age (hazard ratio = 2.41; 95% CI: 1.24 to 4.71 for ≥43 vs. ≤34 years), and lower in those receiving ART for >30 months. CONCLUSIONS: Our findings underline the importance of optimal treatment adherence and adequate virological response monitoring and emphasize the need for resistance surveillance initiatives even in HIV programs achieving high virological suppression rates.
Authors: Janet Karpinski; Ilona Hauber; Jan Chemnitz; Carola Schäfer; Maciej Paszkowski-Rogacz; Deboyoti Chakraborty; Niklas Beschorner; Helga Hofmann-Sieber; Ulrike C Lange; Adam Grundhoff; Karl Hackmann; Evelin Schrock; Josephine Abi-Ghanem; M Teresa Pisabarro; Vineeth Surendranath; Axel Schambach; Christoph Lindner; Jan van Lunzen; Joachim Hauber; Frank Buchholz Journal: Nat Biotechnol Date: 2016-02-22 Impact factor: 54.908
Authors: Matthew D Hickey; Dan Omollo; Charles R Salmen; Brian Mattah; Cinthia Blat; Gor Benard Ouma; Kathryn J Fiorella; Betty Njoroge; Monica Gandhi; Elizabeth A Bukusi; Craig R Cohen; Elvin H Geng Journal: AIDS Care Date: 2016-05-04
Authors: Emma R Lee; Neil Parkin; Cheryl Jennings; Chanson J Brumme; Eric Enns; Maria Casadellà; Mark Howison; Mia Coetzer; Santiago Avila-Rios; Rupert Capina; Eric Marinier; Gary Van Domselaar; Marc Noguera-Julian; Don Kirkby; Jeff Knaggs; Richard Harrigan; Miguel Quiñones-Mateu; Roger Paredes; Rami Kantor; Paul Sandstrom; Hezhao Ji Journal: Sci Rep Date: 2020-01-31 Impact factor: 4.379
Authors: Rachel A Silverman; Grace C John-Stewart; Ingrid A Beck; Ross Milne; Catherine Kiptinness; Christine J McGrath; Barbra A Richardson; Bhavna Chohan; Samah R Sakr; Lisa M Frenkel; Michael H Chung Journal: PLoS One Date: 2019-10-04 Impact factor: 3.240